Pertinax Pharma Ltd is delighted to announce the successful closing of its latest £860,000 funding round. The investment was provided by national investors Mercia Fund Managers and Perivoli Innovations, both following on, and new investor Syndicate Room.
Peter Dines, Chief Operating Officer at Mercia, explained their continued support: “Mercia invests in UK technology businesses and we first backed Michele and the Pertinax team as they span out of Bristol University in early 2016. Since then, the team have made great progress in both developing the technology capability and more importantly developing the commercial opportunities. Pertinax’s technology represents an exciting platform for a wide range of uses. There is a huge gap for sustained efficacy and safe antimicrobials across many market verticals.”
James Alexandroff, representing Perivoli Innovations, added: “Perivoli Innovations invests across a wide range of life science opportunities spinning out of UK universities and regards Pertinax to be one of the most exciting on account of the wide implications for its slow release antiseptic product in wound care, wound closure, veterinary, dentistry and many other categories. The product is well protected with a comprehensive patent portfolio and the management team is very strong and well connected.”
CEO of Pertinax, Dr Michele Barbour, said: “We have made some very significant technical progress over the past few months, and this has been matched by some exciting commercial discussions and collaborative projects in the medical device/wound care sector. This new investment comes at an excellent time and will allow us to progress our plans for GMP manufacture and exploitations of further applications of our platform antimicrobial technology. We are delighted that our cornerstone investors, who have been with us from the start, have followed their investments a third time, and we are excited to bring Syndicate Room on board alongside Mercia and Perivoli.”